Bruininks-oseretsky Test Of Motor Proficiency Second Edition Bot 2

Bruininks-Oseretsky Test of Motor Proficiency – Second Edition (BOT-2) Bruininks & Bruininks (2005) 4;0–21;11 Norm-referenced, clinician administered Performance items, including fine-motor tasks, such as copying and tracing, and gross-motor tasks, such as sit-ups and running speed Complete form: 45–60 min. Each composite: 10– 15 min. Or living in remote Australian Aboriginal communities. Test of Motor Proficiency Second Edition (BOT. BOT-2, Bruininks-Oseretsky Test of Motor. A Critical Review of the Bruininks-Oseretsky Test of Motor Proficiency. Title: Bruininks-Oseretsky Test of Motor Proficiency (BOT-2) Edition: Second Edition. Dates of Publication and Revision: 1 st ed. 1978; 2 nd ed 2005. Authors: Bruininks, Robert H., Bruininks, Brett D. NARRATIVE REPORT The Bruininks-Oseretsky Test of Motor Proficiency, Second Edition (BOT-2) is an individually administered test that uses engaging, goal-directed.

Background The Lililwan Project is the first population-based study to determine Fetal Alcohol Spectrum Disorders (FASD) prevalence in Australia and was conducted in the remote Fitzroy Valley in North Western Australia. The diagnostic process for FASD requires accurate assessment of gross and fine motor functioning using standardised cut-offs for impairment. The Bruininks-Oseretsky Test of Motor Proficiency, Second Edition (BOT-2) is a norm-referenced assessment of motor function used worldwide and in FASD clinics in North America. It is available in a Complete Form with 53 items or a Short Form with 14 items. Its reliability in measuring motor performance in children exposed to alcohol in utero or living in remote Australian Aboriginal communities is unknown. Methods A prospective inter-rater and test-retest reliability study was conducted using the BOT-2 Short Form. A convenience sample of children (n = 30) aged 7 to 9 years participating in the Lililwan Project cohort (n = 108) study, completed the reliability study.

Over 50% of mothers of Lililwan Project children drank alcohol during pregnancy. Two raters simultaneously scoring each child determined inter-rater reliability. Test-retest reliability was determined by assessing each child on a second occasion using predominantly the same rater. Reliability was analysed by calculating Intra-Class correlation Coefficients, ICC(2,1), Percentage Exact Agreement (PEA) and Percentage Close Agreement (PCA) and measures of Minimal Detectable Change (MDC) were calculated. Results Thirty Aboriginal children (18 male, 12 female: mean age 8.8 years) were assessed at eight remote Fitzroy Valley communities. The inter-rater reliability for the BOT-2 Short Form score sheet outcomes ranged from 0.88 (95%CI, 0.77 – 0.94) to 0.92 (95%CI, 0.84 – 0.96) indicating excellent reliability. The test-retest reliability (median interval between tests being 45.5 days) for the BOT-2 Short Form score sheet outcomes ranged from 0.62 (95%CI, 0.34 – 0. Quest Software Keygen Cracks. 80) to 0.73 (95%CI, 0.50 – 0.86) indicating fair to good reliability.

The raw score MDC was 6.12. Introduction In 2010, Aboriginal communities in remote north Western Australia initiated Australia’s first study of the prevalence of Fetal Alcohol Spectrum Disorders (FASD) to better understand the support services required to assist children and their families into the future [ ]. This study, called the Lililwan Project, arose following concerns from Aboriginal leaders about the effect that high-risk drinking was having on the development of children within their communities [ ] and the potential for FASD. FASD refers to a spectrum of lifelong physical, behavioural and neurodevelopmental disorders resulting from brain injury caused by prenatal alcohol exposure (PAE) [, ]. Clinicians have suspected 30% or higher of the population in some remote Australian Aboriginal communities may have FASD where drinking rates are high [ ]. The Lililwan Project will provide the first data for these communities. Diagnostic process Diagnosis of FASD is complex, involving assessment for facial dysmorphology, growth deficiency and central nervous system (CNS) impairment or structural abnormalities.